{"commentary":{"count":217,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":83,"youtube":75,"podcast":53,"x_video":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04821622\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04821622","nct_id":"NCT04821622","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04821622. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Talazoparib plus enzalutamide","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Placebo plus enzalutamide","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Astellas Pharma Inc"],"completion_date":{"date":"2027-08-28","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":599,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"talazoparib plus enzalutamide","type":"DRUG"},{"name":"Placebo plus enzalutamide","type":"DRUG"}],"last_update":"2026-09-04","lead_sponsor":"Pfizer","official_title":"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"radiological Progression-Free Survival","timeFrame":"randomization up to 3 years"}],"references":[{"citation":"Agarwal N, Matsubara N, Azad AA, Saad F, Mateo J, Jiang S, Ye D, Voog E, Shore ND, Cil T, Vulsteke C, Chung HJ, Zschabitz S, Laird AD, Zhang X, Nandoskar P, Chetcuti SF, Wang F, Fizazi K. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. N Engl J Med. 2026 Jul 30;395(5):427-439. doi: 10.1056/NEJMoa2604126. Epub 2026 May 30.","pmid":"42223064","type":"DERIVED"},{"citation":"Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar;20(9):493-505. doi: 10.2217/fon-2023-0526. Epub 2023 Oct 26.","pmid":"37882449","type":"DERIVED"}],"start_date":{"date":"2021-05-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","url":"https://clinicaltrials.gov/study/NCT04821622"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04821622"}